CHERIE SOMMER: Open Payments
NPI 1659707669 · LEBANON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$217 in 11 payments from 9 companies in 2025. Trend: 2023 $182 · 2024 $0 · 2025 $217
Food & beverage: $217
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $44 |
| Abbott Laboratories | 2 | $43 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Exact Sciences Corporation | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Merck Sharp & Dohme LLC | 1 | $18 |
| ABBVIE INC. | 1 | $14 |
Products named: CAPLYTA, FREESTYLE LIBRE, REXULTI, Ozempic, Dexcom G6 Transmitter, The Cologuard Plus Collection Kit, JARDIANCE, GARDASIL 9.
Industry payments across MO — which companies pay providers there.
